RELX-INTERNATIONAL
17.5.2022 15:16:11 CEST | Business Wire | Press release
RELX International, a responsible multinational electronic cigarettes company, is continuing its support for the Hashemite Kingdom of Jordan to adopt a more favourable fiscal policy when it comes to the country’s e-cigarette polices and taxes. Should policies and taxes on these products be revised in line with regional markets such as Egypt, Kuwait, Saudi Arabia and the UAE, Jordanian adult smokers, the business environment and government financial reserves will benefit greatly.
According to the Jordan National Stepwise Survey (STEPs) for Noncommunicable Diseases Risk Factors 2019, adult smokers in Jordan smoke an average of 21.3 cigarettes a day [1]. The rate is said to be amongst the highest in the world, with worldwide scientific research linking high tobacco use to a raft of diseases. In contrast, an increasing number of reputed organisations including the UK’s National Health Service (NHS) has said that e-cigarettes are far less harmful than traditional cigarettes, and can actually help smokers reduce or quit smoking altogether [2].
For adult smokers in Jordan, reforming e-cigarette policies and reducing taxes will bring legal access to accessibly priced, premium quality e-cigarette products, which are backed by the latest research & development. Responsible brands will also be able to work closer with their partners to educate adult consumers about the risks and benefits of their products, and restrict access to minors. Consumers can also rest assured that regulated products have been signed off by the Jordanian Food and Drug Administration, which is the sole national competent authority for drug safety & efficacy and food safety & quality.
While e-cigarette products do contain nicotine and so are not completely without risks, the latter is not the main cause of smoking-related diseases according to various regulatory and health organisations including the aforementioned NHS. In fact, a research paper published on the website ‘Tobacco Control’ has stated that the replacement of combustible cigarettes by e-cigarettes use over a 10-year period yields 6.6-million fewer premature deaths, with 86.7-million fewer life years lost in the Optimistic Scenario in the United States alone [3].
Apart from the benefit to adult smokers in the country, broad e-cigarette reforms will benefit the business and investment environment in Jordan. E-cigarette vendors will be attracted to investing in on-ground facilities to better liaise with the market, while the supply chain responsible for the distribution of products could also experience significant growth; traditionally, e-cigarette products are retailed by small- and medium-businesses, and the legalisation of these products with balanced taxation will attract entrepreneurs keen to set up new retail points across the country.
Through these important reforms, Jordanian authorities will also benefit from the collection of tax revenues from legally imported products. In line with this, authorities will be able to clamp down on tax evasion issues associated with illegal market players, while simultaneously working to curtail the spread of inferior and dangerous black-market products, which do not meet the standards and regulations outlined by local and international authorities. This will positively impact the safety of adult smokers who will be able to access licensed and standard-compliant e-cigarette products at an accessible price.
Links:
[1] Jordan National Stepwise Survey (STEPs) for Noncommunicable Diseases Risk Factors 2019
[2] NHS UK - Using e-cigarettes to stop smoking
[3] Tobacco Control – Potential deaths averted in USA by replacing cigarettes with e-cigarettes
Notes to Editors:
About RELX International
Founded in 2019, RELX International is a multinational electronic cigarettes company that markets and sells RELX, The world’s advanced vape brand powered by SuperSmoothTM technology. RELX, Asia’s leading e-cigarette brand, is widening its footprint across the world, and is currently available in 40+ countries such as the UK, France, Italy, Germany, Indonesia, Philippines, Canada, KSA and the UAE. What sets RELX apart from competition is the fact that it has a full ecosystem (such as closed pods, disposables, device, and power bank accessories) that are designed at a cutting-edge research and development center and produced at one of the world’s largest e-cigarette factories. RELX's mission is to make RELX a trusted brand for legal age adult smokers through state-of-the-art products, industry-leading technologies, and scientific advances in collaboration with talented and committed people around the globe. The company has attracted global talents from Uber, Procter & Gamble, Apple, Beats, and L'Oréal. RELX is proud to be listed in Dubai Duty Free, the first duty free channel in the world.
RELX's Social Media
LinkedIn: RELX International
Instagram: @RELXArabia
Facebook: @RELXArabia
View source version on businesswire.com: https://www.businesswire.com/news/home/20220428005655/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
